Actinogen ACW0002
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects with Mild Dementia due to Alzheimer’s Disease (AD)
